Flexipharm Austrading announces launch of Arsenic Trioxide Phebra (arsenic trioxide 1mg/ml concentrate for solution for infusion)

Secure supply and first vial presentation of a pivotal drug for acute promyelocytic leukaemia

FARNBOROUGH, England, May 20, 2019: Flexipharm Austrading the UK specialty pharmaceutical company focused on supplying the NHS with Better. Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.

Arsenic Trioxide Phebra is a glass vial presentation of arsenic trioxide 1mg/ml concentrate solution for infusion, a NICE-recommended treatment (in combination with all-trans retinoic acid) for newly diagnosed low-intermediate risk and relapsed acute promyelocytic leukaemia or APML1,2.

Arsenic Trioxide Phebra is the first generic arsenic trioxide injection product to be launched in the UK and the first in a preferred vial presentation. The product is supplied by Flexipharm Austrading’s partner, Phebra Pty Ltd, an Australian-based development and manufacturing company which has a successful track record in the supply of arsenic trioxide injection (www.phebra.com).

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH